138 related articles for article (PubMed ID: 8336169)
1. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.
van Diemen HA; Polman CH; van Dongen MM; Nauta JJ; Strijers RL; van Loenen AC; Bertelsmann FW; Koetsier JC
J Neurol Sci; 1993 Jun; 116(2):220-6. PubMed ID: 8336169
[TBL] [Abstract][Full Text] [Related]
2. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.
Van Diemen HA; Polman CH; Koetsier JC; Van Loenen AC; Nauta JJ; Bertelsmann FW
Clin Neuropharmacol; 1993 Jun; 16(3):195-204. PubMed ID: 8504436
[TBL] [Abstract][Full Text] [Related]
3. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.
Rossini PM; Pasqualetti P; Pozzilli C; Grasso MG; Millefiorini E; Graceffa A; Carlesimo GA; Zibellini G; Caltagirone C
Mult Scler; 2001 Dec; 7(6):354-8. PubMed ID: 11795455
[TBL] [Abstract][Full Text] [Related]
4. 4-Aminopyridine in multiple sclerosis: prolonged administration.
Stefoski D; Davis FA; Fitzsimmons WE; Luskin SS; Rush J; Parkhurst GW
Neurology; 1991 Sep; 41(9):1344-8. PubMed ID: 1891078
[TBL] [Abstract][Full Text] [Related]
5. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
Davis FA; Stefoski D; Rush J
Ann Neurol; 1990 Feb; 27(2):186-92. PubMed ID: 2317014
[TBL] [Abstract][Full Text] [Related]
6. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
van Diemen HA; Polman CH; van Dongen TM; van Loenen AC; Nauta JJ; Taphoorn MJ; van Walbeek HK; Koetsier JC
Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
[TBL] [Abstract][Full Text] [Related]
7. Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
Zeller D; Reiners K; Bräuninger S; Buttmann M
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):707-9. PubMed ID: 24357684
[No Abstract] [Full Text] [Related]
8. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis.
Fujihara K; Miyoshi T
J Neurol Sci; 1998 Jul; 159(1):102-6. PubMed ID: 9700711
[TBL] [Abstract][Full Text] [Related]
9. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
[TBL] [Abstract][Full Text] [Related]
10. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
Smits RC; Emmen HH; Bertelsmann FW; Kulig BM; van Loenen AC; Polman CH
Neurology; 1994 Sep; 44(9):1701-5. PubMed ID: 7936300
[TBL] [Abstract][Full Text] [Related]
11. Lidocaine unmasks silent demyelinative lesions in multiple sclerosis.
Sakurai M; Mannen T; Kanazawa I; Tanabe H
Neurology; 1992 Nov; 42(11):2088-93. PubMed ID: 1331868
[TBL] [Abstract][Full Text] [Related]
12. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Horton L; Conger A; Conger D; Remington G; Frohman T; Frohman E; Greenberg B
Neurology; 2013 May; 80(20):1862-6. PubMed ID: 23616154
[TBL] [Abstract][Full Text] [Related]
13. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
Bever CT; Young D; Anderson PA; Krumholz A; Conway K; Leslie J; Eddington N; Plaisance KI; Panitch HS; Dhib-Jalbut S
Neurology; 1994 Jun; 44(6):1054-9. PubMed ID: 8208399
[TBL] [Abstract][Full Text] [Related]
14. 4-Aminopyridine improves clinical signs in multiple sclerosis.
Stefoski D; Davis FA; Faut M; Schauf CL
Ann Neurol; 1987 Jan; 21(1):71-7. PubMed ID: 2435223
[TBL] [Abstract][Full Text] [Related]
15. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
Schwid SR; Petrie MD; McDermott MP; Tierney DS; Mason DH; Goodman AD
Neurology; 1997 Apr; 48(4):817-21. PubMed ID: 9109861
[TBL] [Abstract][Full Text] [Related]
16. The current status of studies of aminopyridines in patients with multiple sclerosis.
Bever CT
Ann Neurol; 1994; 36 Suppl():S118-21. PubMed ID: 8017870
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of eye movement registration and visual evoked potentials in evaluation of therapy in patients with multiple sclerosis.
van Dongen MM; Bertelsmann FW; Polman CH
J Neurol Sci; 1991 Mar; 102(1):25-31. PubMed ID: 1856729
[TBL] [Abstract][Full Text] [Related]
18. Effects of 4-aminopyridine in patients with multiple sclerosis.
Jones RE; Heron JR; Foster DH; Snelgar RS; Mason RJ
J Neurol Sci; 1983; 60(3):353-62. PubMed ID: 6631441
[TBL] [Abstract][Full Text] [Related]
19. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury.
Hayes KC; Potter PJ; Wolfe DL; Hsieh JT; Delaney GA; Blight AR
J Neurotrauma; 1994 Aug; 11(4):433-46. PubMed ID: 7837283
[TBL] [Abstract][Full Text] [Related]
20. Aminopyridines for symptomatic treatment in multiple sclerosis.
Solari A; Uitdehaag B; Giuliani G; Pucci E; Taus C
Cochrane Database Syst Rev; 2002; (4):CD001330. PubMed ID: 12804404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
